Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.

Atrial natriuretic factor influences renal diurnal rhythm in essential hypertension.

Characterization of atrial natriuretic peptide in urine from rats treated with a neutral endopeptidase inhibitor.

Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers.

Effects of ketanserin on lipids, lipoproteins, and plasma atrial natriuretic factor in patients with essential hypertension.

Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor.

Renal sites of action of physiological increases in plasma atrial natriuretic factor concentration in essential hypertension.

[Atrial natriuretic factor].

Atrial natriuretic peptides in plasma.

Atrial natriuretic factor.

Dysregulation of atrial natriuretic factor in hypertension-prone man.

Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and C-ANP receptor ligand in the rat.

Plasma insulin levels do not change during atrial natriuretic factor infusion in human essential hypertensives.

Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism.

Receptors of atrial natriuretic factor.

Plasma atrial natriuretic peptide in elite runners.

Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites.

Atrial natriuretic factor (ANF) is a potent bronchodilator in asthma.

Degradation and inactivation of rat atrial natriuretic peptide 1-28 by neutral endopeptidase-24.11 in rat pulmonary membranes.

Atrial natriuretic factor and transmural pressures.

Atrial natriuretic factor and related peptide hormones.

Atrial natriuretic factor in experimental cirrhosis.

Atrial natriuretic factor and cardiopulmonary bypass.

Atrial natriuretic factor in edematous disorders.

hypertension syndrome, and an elevated atrial natriuretic factor.

Suggest Documents

Atrial natriuretic factor influences renal diurnal rhythm in essential hypertension.

Characterization of atrial natriuretic peptide in urine from rats treated with a neutral endopeptidase inhibitor.

Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers.

Effects of ketanserin on lipids, lipoproteins, and plasma atrial natriuretic factor in patients with essential hypertension.

Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor.

Renal sites of action of physiological increases in plasma atrial natriuretic factor concentration in essential hypertension.

[Atrial natriuretic factor].

Atrial natriuretic peptides in plasma.

Atrial natriuretic factor.

Dysregulation of atrial natriuretic factor in hypertension-prone man.

Response to atrial natriuretic peptide, endopeptidase 24.11 inhibitor and C-ANP receptor ligand in the rat.

Plasma insulin levels do not change during atrial natriuretic factor infusion in human essential hypertensives.

Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism.

Receptors of atrial natriuretic factor.

Plasma atrial natriuretic peptide in elite runners.

Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites.

Atrial natriuretic factor (ANF) is a potent bronchodilator in asthma.

Degradation and inactivation of rat atrial natriuretic peptide 1-28 by neutral endopeptidase-24.11 in rat pulmonary membranes.

Atrial natriuretic factor and transmural pressures.

Atrial natriuretic factor and related peptide hormones.

Atrial natriuretic factor in experimental cirrhosis.

Atrial natriuretic factor and cardiopulmonary bypass.

Atrial natriuretic factor in edematous disorders.

hypertension syndrome, and an elevated atrial natriuretic factor.

Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.

Recommend Documents

Follow Us